(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Alx Oncology Holdings's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ALXO's revenue for 2028 to be $7,470,918,704, with the lowest ALXO revenue forecast at $7,470,918,704, and the highest ALXO revenue forecast at $7,470,918,704. On average, 1 Wall Street analysts forecast ALXO's revenue for 2029 to be $800,053,942, with the lowest ALXO revenue forecast at $800,053,942, and the highest ALXO revenue forecast at $800,053,942.
In 2030, ALXO is forecast to generate $725,617,866 in revenue, with the lowest revenue forecast at $725,617,866 and the highest revenue forecast at $725,617,866.